Skip to main content

Breaking News
  • ICC says Kenyan president’s trial to start on Nov 12
| |

$11.8 billion is the price Nestle is going to pay for US firm Pfizer’s infant nutrition business . That is about two billion more than the maximum expected by investors.

In Behind Markets we look at the reasons for the high price and the effects it had.

Click on the link above to see the report

More about: , ,

Copyright © 2013 euronews

| |

JavaScript is required in order to view this article’s accompanying video


Log in
Please enter your login details